• 
• See all for GuruFocus
• View Print Version

More from GuruFocus

• A Strategy Ben Graham Used for 30 Years
• Are CEOs Buying?
• Market Overvalued, How to Invest?

Referenced Stocks

• SURG 0% Rate It

Shares of Synergetics ( SURG ) are up almost 30% today after the company's eye surgery device was approved by U.S. health regulators. The device serves the purpose of removing liquid from inside an eye during surgery. The company is also waiting for approval from European authorities on the same device.

At the time of writing, shares of Synergetics are at $4.96, up $1.09 so far today, or 28.17%. Synergetics designs, manufactures and markets medical devices for use primarily in ophthalmic surgery and neurosurgery and for other healthcare applications. Synergetics USA Inc. has a market cap of $96.7 million; its shares were traded at around $4.95 with a P/E ratio of 16 and P/S ratio of 1.7. Synergetics USA Inc. had an annual average earnings growth of 13.7% over the past five years.

CEO David Hable recently purchased 4,000 shares of the company on 6/14/2012 at an average price of $4.03. On 3/15/2012, he had also purchased 4,000 shares. CFO Pamela Boone also bought 2,800 shares of the company at an average price of $4. There were various trades from other insiders as well.

Read More:

About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.